SEC Comment Letter 0000000000-25-001052 to KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880) (KZIA)
KAZIA THERAPEUTICS LTD (KZIA) (CIK 0001075880)
Date: Jan. 31, 2025 · CIK: 0001075880 · Accession: 0000000000-25-001052
AI Filing Summary & Sentiment
File numbers found in text: 333-284606
Letter
January 31, 2025 John Friend Chief Executive Officer and Director Kazia Therapeutics Limited Three International Towers Level 24 300 Barangaroo Avenue Sydney, NSW, 2000, Australia Re:Kazia Therapeutics Limited Registration Statement on Form F-1 Filed January 30, 2025 File No. 333-284606 Dear John Friend: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc:Stephanie Richards, Esq.
Show Raw Text
January 31, 2025
John Friend
Chief Executive Officer and Director
Kazia Therapeutics Limited
Three International Towers Level 24
300 Barangaroo Avenue
Sydney, NSW, 2000, Australia
Re:Kazia Therapeutics Limited
Registration Statement on Form F-1
Filed January 30, 2025
File No. 333-284606
Dear John Friend:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:Stephanie Richards, Esq.